| Efficacy of NVX-CoV2373 Covid-19 vaccine against the B. 1.351 variant V Shinde, S Bhikha, Z Hoosain, M Archary, Q Bhorat, L Fairlie, U Lalloo, ... New England Journal of Medicine 384 (20), 1899-1909, 2021 | 729 | 2021 |
| Efficacy and safety of dolutegravir with emtricitabine and tenofovir alafenamide fumarate or tenofovir disoproxil fumarate, and efavirenz, emtricitabine, and tenofovir … S Lockman, SS Brummel, L Ziemba, L Stranix-Chibanda, K McCarthy, ... The Lancet 397 (10281), 1276-1292, 2021 | 141 | 2021 |
| Novavax NVX-COV2373 triggers neutralization of Omicron sub-lineages JN Bhiman, SI Richardson, BE Lambson, P Kgagudi, N Mzindle, ... Scientific reports 13 (1), 1222, 2023 | 54 | 2023 |
| Immunogenicity and safety of a SARS-CoV-2 recombinant spike protein nanoparticle vaccine in people living with and without HIV-1 infection: a randomised, controlled, phase 2A … SA Madhi, D Moodley, S Hanley, M Archary, Z Hoosain, U Lalloo, C Louw, ... The Lancet HIV 9 (5), e309-e322, 2022 | 50 | 2022 |
| Pharmacokinetics, safety, tolerability, and antiviral activity of dolutegravir dispersible tablets in infants and children with HIV-1 (IMPAACT P1093): results of an open-label … TD Ruel, EP Acosta, JP Liu, KP Gray, K George, N Montañez, S Popson, ... The Lancet HIV 9 (5), e332-e340, 2022 | 29 | 2022 |
| Efficacy and safety of three antiretroviral therapy regimens started in pregnancy up to 50 weeks post partum: a multicentre, open-label, randomised, controlled, phase 3 trial L Chinula, L Ziemba, S Brummel, K McCarthy, A Coletti, C Krotje, ... The Lancet HIV 10 (6), e363-e374, 2023 | 21 | 2023 |
| IMPAACT 2010/VESTED Study Team and Investigators. Efficacy and safety of dolutegravir with emtricitabine and tenofovir alafenamide fumarate or tenofovir disoproxil fumarate … S Lockman, SS Brummel, L Ziemba, L Stranix-Chibanda, K McCarthy, ... Lancet 397 (10281), 1276-1292, 2021 | 20 | 2021 |
| The multi-country PROMOTE HIV antiretroviral treatment observational cohort in Sub-Saharan Africa: Objectives, design, and baseline findings TE Taha, N Yende-Zuma, J Aizire, T Chipato, L Wambuzi Ogwang, ... PloS one 13 (12), e0208805, 2018 | 20 | 2018 |
| Obesity in young South African women living with HIV: A cross-sectional analysis of risk factors for cardiovascular disease S Hanley, D Moodley, M Naidoo PloS one 16 (11), e0255652, 2021 | 15 | 2021 |
| Factors associated with unsuppressed viremia in women living with HIV on lifelong ART in the multi-country US-PEPFAR PROMOTE study: a cross-sectional analysis P Atuhaire, S Hanley, N Yende-Zuma, J Aizire, L Stranix-Chibanda, ... PLoS One 14 (10), e0219415, 2019 | 15 | 2019 |
| Acceptability and tolerability of long-acting injectable cabotegravir or rilpivirine in the first cohort of virologically suppressed adolescents living with HIV (IMPAACT 2017 … ED Lowenthal, J Chapman, R Ohrenschall, K Calabrese, K Baltrusaitis, ... The Lancet HIV 11 (4), e222-e232, 2024 | 10 | 2024 |
| Safety and pharmacokinetics of oral and long-acting injectable cabotegravir or long-acting injectable rilpivirine in virologically suppressed adolescents with HIV (IMPAACT 2017 … AH Gaur, EV Capparelli, K Calabrese, K Baltrusaitis, MA Marzinke, ... The Lancet HIV 11 (4), e211-e221, 2024 | 9 | 2024 |
| Pharmacokinetics and safety of maraviroc in neonates JC Rosebush, BM Best, EG Chadwick, K Butler, J Moye, E Smith, ... Aids 35 (3), 419-427, 2021 | 9 | 2021 |
| Weight Changes and Adverse Pregnancy Outcomes With Dolutegravir-and Tenofovir Alafenamide Fumarate–Containing Antiretroviral Treatment Regimens During Pregnancy and Postpartum RM Hoffman, S Brummel, L Ziemba, L Chinula, K McCarthy, L Fairlie, ... Clinical Infectious Diseases 78 (6), 1617-1628, 2024 | 8 | 2024 |
| Slow acceptance of universal antiretroviral therapy (ART) among mothers enrolled in IMPAACT PROMISE studies across the globe L Stranix-Chibanda, S Brummel, J Pilotto, M Mutambanengwe, ... AIDS and Behavior 23, 2522-2531, 2019 | 8 | 2019 |
| Dolutegravir as first-line antiretroviral therapy in South Africa: Beware the one-size-fits-all approach A Bangalee, S Hanley, V Bangalee South African Medical Journal 112 (10), 787-790, 2022 | 7 | 2022 |
| Primary prevention of cardiovascular disease in South African women living with HIV S Hanley South African Family Practice 61 (6), 273-275, 2019 | 7 | 2019 |
| Effects of long-term antiretroviral therapy in reproductive-age women in sub-Saharan Africa (the PEPFAR PROMOTE study): a multi-country observational cohort study TE Taha, N Yende-Zuma, SS Brummel, L Stranix-Chibanda, LW Ogwang, ... The Lancet HIV 9 (6), e394-e403, 2022 | 6 | 2022 |
| Efficacy and safety of dolutegravir-and tenofovir alafenamide fumarate-containing HIV antiretroviral treatment regimens started in pregnancy: a randomised controlled trial S Lockman, SS Brummel, L Ziemba, L Stranix-Chibanda, K McCarthy, ... Lancet (London, England) 397 (10281), 1276, 2021 | 6 | 2021 |
| Neurodevelopmental outcomes of HIV/antiretroviral drug perinatally exposed uninfected children aged 3–6 years MG Fowler, C Hanrahan, N Yende, L Stranix-Chibanda, T Chipato, ... AIDS 36 (11), 1533-1543, 2022 | 3 | 2022 |
